Acumen Pharmaceuticals, Inc.
ABOS
$2.99
-$0.18-5.54%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -25.09% | -34.76% | -284.65% | -19.37% | 90.06% |
| Gross Profit | 25.09% | 34.76% | 284.65% | 19.37% | -90.06% |
| SG&A Expenses | 2.64% | -8.60% | -7.06% | -9.43% | -4.60% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -22.02% | -30.36% | -36.36% | -17.83% | 71.24% |
| Operating Income | 22.02% | 30.36% | 36.36% | 17.83% | -71.24% |
| Income Before Tax | 20.10% | 27.99% | 32.34% | 11.13% | -99.40% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 20.10% | 27.99% | 32.34% | 11.13% | -99.40% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 20.10% | 27.99% | 32.34% | 11.13% | -99.40% |
| EBIT | 22.02% | 30.36% | 36.36% | 17.83% | -71.24% |
| EBITDA | 22.02% | 30.37% | 36.37% | 17.83% | -71.29% |
| EPS Basic | 33.02% | 31.06% | 32.89% | 11.85% | -97.78% |
| Normalized Basic EPS | 33.02% | 31.07% | 32.88% | 11.85% | -97.80% |
| EPS Diluted | 33.02% | 31.06% | 32.89% | 11.85% | -97.78% |
| Normalized Diluted EPS | 33.02% | 31.07% | 32.88% | 11.85% | -97.80% |
| Average Basic Shares Outstanding | 19.28% | 4.45% | 0.82% | 0.82% | 0.82% |
| Average Diluted Shares Outstanding | 19.28% | 4.45% | 0.82% | 0.82% | 0.82% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |